


FLAURA2 results demonstrate osimertinib plus chemotherapy superior compared to osimertinib alone

September 11 2023



Credit: Unsplash/CC0 Public Domain



Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the <u>International Association for the Study of Lung Cancer</u> (IASLC) 2023 World Conference on Lung Cancer in Singapore.

The FLAURA2 study was led by Dr. Pasi A. Jänne from the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Mass.

Osimertinib, a potent third-generation EGFR-TKI with central nervous system activity, has garnered attention for its targeted inhibition of both sensitizing and resistance EGFR mutations. According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs.

The study enrolled 557 patients and randomized them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy. The combination arm involved a regimen of osimertinib (80mg daily) alongside pemetrexed and either cisplatin or carboplatin.

"Results from the study demonstrated a remarkable improvement in progression-free survival (PFS) with the osimertinib plus chemotherapy approach, showcasing a statistically significant reduction in disease progression risk compared to osimertinib monotherapy," Dr. Jänne said.

The data showed a compelling hazard ratio of 0.62 (95% CI 0.49, 0.79; p

Citation: FLAURA2 results demonstrate osimertinib plus chemotherapy superior compared to osimertinib alone (2023, September 11) retrieved 14 May 2024 from https://medicalxpress.com/news/2023-09-flaura2-results-osimertinib-chemotherapy-



superior.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.